Patents by Inventor Harpreet Singh

Harpreet Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11986497
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: February 9, 2023
    Date of Patent: May 21, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
  • Patent number: 11975058
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: May 7, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11975042
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: May 7, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 11970444
    Abstract: Disclosed herein is an efficacious process for preparation of highly purified Glycopyrrolate tosylate in high yield. The process is being cost effective, environment friendly and easily scalable to high volume industrial production.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: April 30, 2024
    Assignee: HARMAN FINOCHEM LIMITED
    Inventors: Vijay Trimbak Kadam, Dhananjay Uddhavrao Ed Aki, Ravindra Bhausaheb Pagire, Mayur Sanjay Kulkarni, Harpreet Singh Minhas, Gurpreet Singh Minhas
  • Patent number: 11969455
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: April 30, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 11965013
    Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: April 23, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Publication number: 20240127522
    Abstract: Examples are disclosed that relate to generating expressive avatars using multi-modal three-dimensional face modeling and tracking. One example includes a computer system comprising a processor coupled to a storage system that stores instructions. Upon execution by the processor, the instructions cause the processor to receive initialization data describing an initial state of a facial model. The instructions further cause the processor to receive a plurality of multi-modal data signals. The instructions further cause the processor to perform a fitting process using the initialization data and the plurality of multi-modal data signals. The instructions further cause the processor to determine a set of parameters based on the fitting process, wherein the determined set of parameters describes an updated state of the facial model.
    Type: Application
    Filed: December 6, 2022
    Publication date: April 18, 2024
    Applicant: Microsoft Technology Licensing, LLC
    Inventors: Harpreet Singh SAWHNEY, Benjamin Eliot LUNDELL, Anshul Bhavesh SHAH, Calin CRISTIAN, Charles Thomas HEWITT, Tadas BALTRUSAITIS, Mladen RADOJEVIC, Kosta GRUJCIC, Ivan STOJILJKOVIC, Paul Malcolm MCILROY, John Ishola OLAFENWA, Jouya JADIDIAN, Kenneth Mitchell JAKUBZAK
  • Patent number: 11957730
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: April 16, 2024
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 11957742
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: January 24, 2023
    Date of Patent: April 16, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Publication number: 20240119497
    Abstract: According to some embodiments, in an environment where one or more users can view video content on respective user systems, wherein each user system comprises a display screen, systems and methods are provided for enabling at least one user to shop directly from the display screen on a respective user system while viewing video content.
    Type: Application
    Filed: December 11, 2023
    Publication date: April 11, 2024
    Inventors: Harpreet Singh Geekee, Gurpreet Singh Rai, Christopher James Kelly
  • Patent number: 11951160
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: April 9, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11945850
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: April 2, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Colette Song, Heiko Schuster, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
  • Patent number: 11939366
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: March 26, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11939401
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: March 26, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • Patent number: 11938176
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: March 26, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Colette Song
  • Patent number: 11939400
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an WIC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: March 26, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • Publication number: 20240095788
    Abstract: Apparatus and method for a scalable pricing engine. A scalable pricing engine is operable in a low-scale mode and a high-scale or scalable mode to process pricing data in response to pricing requests. The pricing engine operates in a first runtime environment in the low-scale mode in which it can service pricing requests up to a threshold number and in which the pricing data can be updated and tested. The pricing engine also operates in a second runtime environment which is a scalable runtime supporting pricing requests above the specified threshold. The scalable runtime and pricing engine rely on a scalable read-only data service which distributes a read-only copy of at least a portion of the pricing data from the primary database, a high-scale cache to reduce access latency, data processing and network resource allocations, and data reduction techniques when processing requests and responses.
    Type: Application
    Filed: September 20, 2022
    Publication date: March 21, 2024
    Applicant: Salesforce, Inc.
    Inventors: Parth Vijay Vaishnav, Thomas Jones, Mitchell Christensen, Daniel May, Harpreet Singh, Jalaleldeen Aref
  • Patent number: 11934778
    Abstract: Certain aspects of the present disclosure provide techniques for providing sentiment analysis of content. In order to determine the overall sentiment of content, a request is received by a sentiment analyzer, which then identifies a content identification number and retrieves comments associated with the content identification number. The sentiment analyzer pre-processes the comments, which includes removing all personal identifying information from the comments. The sentiment analyzer sends the pre-processed comments to a natural language processing service, and in turn, receives sentiment indications corresponding to the comments provided. Based on the sentiment scores, the sentiment analyzer generates a sentiment analysis and displays the sentiment analysis in the graphical user interface generated by the sentiment analyzer.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: March 19, 2024
    Assignee: Intuit, Inc.
    Inventors: Harpreet Singh Hira, Abhay Dhundiraju Sastry, Priyadarshini Rajendran, Sanmathi Sathyanarayana Naga, Tak Yiu Daniel Li, Majo Paulose, Jasen Paul Stine, Darpan Sharma, Nicholas Allen McHenry
  • Patent number: 11932678
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: March 19, 2024
    Assignee: Immatics Biotechnologies GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Publication number: 20240083947
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: June 30, 2023
    Publication date: March 14, 2024
    Inventors: Andrea MAHR, Toni WEINSCHENK, Colette SONG, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH